Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07360522 · ClinicalTrials.gov registry record
Data Collection For Adventitious Lung Sounds Algorithm Using Eko Digital Devices in a Clinical Setting
A clinical trial of Lung Diseases, sponsored by Eko Devices.
- Active
- Registry status
- 750
- Enrollment target
- 1
- Study location
NCT07360522: Active study of Lung Diseases, sponsored by Eko Devices.
NCT07360522 is a study of Lung Diseases that is active but no longer recruiting, run by Eko Devices. The registered enrollment target is 750 participants, roughly in line with the 715-participant average among 31 other Lung Diseases trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07360522, a study of Lung Diseases, is active but no longer recruiting, sponsored by Eko Devices.
- ACTIVE NOT RECRUITING
- Registry status
- 750 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to collect patient lung sounds in order to develop an artificial machine learning algorithm that can potentially tell a doctor if a patient is at risk of certain lung conditions.
Primary Outcome
The primary objective of this study is to collect normal and abnormal lung sounds of up to 750 patients per study site, by having clinicians use the Eko CORE and/or Eko CORE 500 device(s) in real clinical settings, as part of standard of care clinical practice which will then be used to explore an ML algorithm for classifiers for wheeze, coarse crackle, fine crackle, rhonchus, stridor, rales, and cough, as well as determine any correspondences between the type and/or location of adventitious lun
Conditions Studied
Interventions
- DEVICE Eko digital stethoscopes
Study Locations (1)
Texas
- Care United Research - Forney
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 750 participants |
| Start Date | 2024-08-23 |
| Est. Completion | 2026-03-15 |
What the registry record for NCT07360522 still lists
NCT07360522 is an observational study that tracks outcomes without assigning an intervention. The registered 750 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 715-participant average among 31 other Lung Diseases trials with a reported enrollment target.
The record links to 1 condition, with Lung Diseases appearing as the primary indexed condition, and to 1 intervention - of which Eko digital stethoscopes is the first listed.
NCT07360522 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT07360522 about?
NCT07360522 is a clinical study titled "Data Collection For Adventitious Lung Sounds Algorithm Using Eko Digital Devices in a Clinical Setting". The purpose of this research is to collect patient lung sounds in order to develop an artificial machine learning algorithm that can potentially tell a doctor if a patient is at risk of certain lung conditions.
What is the current status of trial NCT07360522?
This trial is currently active not recruiting. The enrollment target is 750 participants. The study started on 2024-08-23. Estimated completion is 2026-03-15.
What conditions does trial NCT07360522 study?
This clinical trial studies the following conditions: Lung Diseases.
What interventions are being tested in trial NCT07360522?
The interventions under investigation include: Eko digital stethoscopes (DEVICE).
Who is sponsoring clinical trial NCT07360522?
This trial is sponsored by Eko Devices, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07360522 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07360522's enrollment target sits among peer trials
750 9th of 31 higher than 23 of 31 other Lung Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)
RECRUITING · Phase 2
-
Real World Registry for Use of the Ion Endoluminal System
RECRUITING
-
American Lung Association (ALA) Lung Health Cohort
RECRUITING
-
Data Collection Using Eko Digital Devices in a Clinical Setting
RECRUITING
-
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
RECRUITING · Phase 2
-
Deep Functional Phenotyping of the ALA Lung Health Cohort
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02048332 · 750 participants · Phase 1
Donor-Derived Viral Specific T-cells (VSTs)
- NCT02087852 · 750 participants
Kidney Cancer DNA Registry
- NCT02532452 · 750 participants · Phase 2
Third Party Viral Specific T-cells (VSTs)
- NCT03126916 · 750 participants · Phase 3
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI